FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 342:592 February 24, 2000 Number 8 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Dienstag, J. L.

To the Editor: In their study of lamivudine as initial treatment for chronic hepatitis B, Dienstag and colleagues (Oct. 21 issue)¹ state that 34 (52 percent) of 66 patients with compensated liver disease who were positive for serum hepatitis B e antigen and who were given 100 mg of lamivudine daily for 52 weeks had reductions of at least 2 points in the score on the Histologic Activity Index (the primary end point), as assessed by analysis of liver-biopsy specimens obtained at base line and at week 52, as compared with 16 of 71 patients given placebo (23 percent). Similarly, . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.